Mvasi

Digital Pharmacist

The RxWiki Digital Pharmacist stamp of approval lets you know that this content has been created and reviewed by a licensed pharmacist.

Mvasi treats certain types of cancer and glioblastoma. Mvasi is a biosimilar to Avastin.

Mvasi Overview

Reviewed: November 20, 2017
Updated: 

Mvasi is a prescription medication used to treat glioblastoma (GBM), a fast-growing brain tumor. It is also used to treat colorectal cancer, lung cancer, renal cell cancer (a type of cancer that begins in the kidney), and cervical cancer. Mvasi belongs to a group of drugs called antiangiogenic agents, which stops blood vessels that feed tumors from forming. Mvasi is a biosimilar (closely related) product to bevacizumab (Avastin).

This medication is available in an injectable form to be given directly into a vein (IV) by a healthcare professional. You will most likely receive an injection every 2 or 3 weeks.

Common side effects of Mvasi include nose bleeding, headache, and high blood pressure.

How was your experience with ?

First, a little about yourself

Tell us about yourself in a few words?

What tips would you provide a friend before taking ?

What are you taking for?

Choose one
  • Other

How long have you been taking it?

Choose one
  • Less than a week
  • A couple weeks
  • A month or so
  • A few months
  • A year or so
  • Two years or more

How well did work for you?

Did you experience many side effects while taking this drug?

How likely would you be to recommend to a friend?

Mvasi Drug Class

Back to Top

Mvasi is part of the drug class:

Mvasi FDA Warning

Back to Top

GASTROINTESTINAL PERFORATIONS

Gastrointestinal Perforation: Occurs in up to 3.2% of bevacizumab product-treated patients. Discontinue Mvasi for gastrointestinal perforation.

SURGERY AND WOUND HEALING COMPLICATIONS

Surgery and Wound Healing Complications: Discontinue in patients with wound dehiscence. Discontinue at least 28 days prior to elective surgery. Do not initiate Mvasi for at least 28 days after surgery and until the surgical wound is fully healed.

HEMORRHAGE

Severe or fatal hemorrhage, hemoptysis, gastrointestinal bleeding, CNS hemorrhage, and vaginal bleeding are increased in bevacizumab product-treated patients. Do not administer Mvasi to patients with serious hemorrhage or recent hemoptysis.